相关实验视频

Updated: Jul 19, 2025

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

在癌症治疗中使用最近的基因素脱乙酶抑制剂

Roza Parveen¹, Divya Harihar², Biswa Prasun Chatterji³

¹Faculty of Medicine and Health Sciences, Tampere University, Tampere, Finland.

|August 10, 2023

概括

基因脱乙酶抑制剂 (HDACi) 通过向转移和基因调节,在癌症治疗中表现有前途. 最近的临床试验和2019年以来的专利强调了它们作为有效的化疗剂的不断变化的作用.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

癌症转移显著增加死亡率,传统化疗通常具有有限的疗效和严重的副作用.
基因组脱乙酶 (HDAC) 酶对染色质结构和基因调节至关重要,在癌症进展和转移中发挥关键作用.
HDAC 抑制剂 (HDACi) 通过调节基因表达,诱导细胞循环停止和促进癌细胞的亡来提供治疗策略.

研究的目的:

审查目前癌症治疗中HDAC抑制剂的现状.
要突出与HDACi相关的最近的临床试验和专利 (2019年以后).
提供HDACi类,作用机制和在各种癌症中的疗效的概述.

主要方法:

文献综述专注于癌症治疗中的HDAC抑制剂.
对临床前和临床疗效数据的分析.
检查最近的专利和临床试验数据从2019年到现在.

主要成果:

几种HDACi药物 (例如,沃里诺斯塔特,图西迪诺斯塔特) 已获得批准,并在诸如宫癌,淋巴瘤和乳腺癌等各种癌症中表现出有效性.
选择性HDACi亚型,如 tucidinostat,针对特定的HDAC类 (1, 2, 3, 10) 具有有希望的结果.
从2019年起的最新数据表明,HDACi用于癌症治疗的研究和开发正在进行中.

结论:

HDAC 抑制剂代表了癌症治疗的重大进步,提供了更好的疗效和有针对性的机制.
通过临床试验和专利申请对HDACi的持续调查强调了它们作为下一代化疗剂的潜力.
HDACi在多种癌症类型中展示了广泛的适用性,突出了它们的治疗多功能性.

关键词:

HDAC 抑制剂的使用这种药物是HDACi药物.在PTCL中,PTCL就是PTCL.癌症癌症癌症癌症癌症组合疗法是一种组合疗法.这些都是专利,专利.

更多相关视频

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Published on: November 30, 2018

相关概念视频

Spreading of Chromatin Modifications

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Histone Variants at the Centromere

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...

Histone Modification

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...